Myocardial infarction: When and how should we initiate treatment with ACE inhibitors?

Roberto Latini, Aldo P. Maggioni, Giulio Zuanetti

Research output: Contribution to journalArticle

Abstract

Recent trials have shown that angiotensin-converting enzyme (ACE) inhibitors can reduce mortality and the occurrence of severe left ventricular dysfunction (LVD) when started within the first day after acute myocardial infarction and continued for 4-6 weeks thereafter. When started within this time window, ACE inhibitors are safe in relatively unselected myocardial infarction (MI) patients provided they are clinically and hemodynamically stable. GISSI-3, ISIS-4 and CCS-1 studies show that more than half of the lives are saved by ACE inhibitor treatment within the first week of therapy. Although the benefit from ACE inhibitors is larger in patients presenting with congestive heart failure (Killip class > 1), the number of lives saved in patients at low risk, who represent the majority of the population, is relevant. This supports the approach of treating all hemodynamically stable MI patients. Treatment could be stopped after about 1 month in patients without evidence of LVD while those with LVD should follow a long-term therapy with ACE inhibitors.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
JournalCardiology
Volume87
Issue numberSUPPL. 1
Publication statusPublished - Dec 1995

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Myocardial Infarction
Left Ventricular Dysfunction
Therapeutics
Heart Failure
Mortality
Population

Keywords

  • Angiotensin-converting enzyme
  • Clinical trials
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial infarction : When and how should we initiate treatment with ACE inhibitors? / Latini, Roberto; Maggioni, Aldo P.; Zuanetti, Giulio.

In: Cardiology, Vol. 87, No. SUPPL. 1, 12.1995, p. 16-22.

Research output: Contribution to journalArticle

Latini, R, Maggioni, AP & Zuanetti, G 1995, 'Myocardial infarction: When and how should we initiate treatment with ACE inhibitors?', Cardiology, vol. 87, no. SUPPL. 1, pp. 16-22.
Latini, Roberto ; Maggioni, Aldo P. ; Zuanetti, Giulio. / Myocardial infarction : When and how should we initiate treatment with ACE inhibitors?. In: Cardiology. 1995 ; Vol. 87, No. SUPPL. 1. pp. 16-22.
@article{1c7aa27c3d5945898ff936b5fdad6d3e,
title = "Myocardial infarction: When and how should we initiate treatment with ACE inhibitors?",
abstract = "Recent trials have shown that angiotensin-converting enzyme (ACE) inhibitors can reduce mortality and the occurrence of severe left ventricular dysfunction (LVD) when started within the first day after acute myocardial infarction and continued for 4-6 weeks thereafter. When started within this time window, ACE inhibitors are safe in relatively unselected myocardial infarction (MI) patients provided they are clinically and hemodynamically stable. GISSI-3, ISIS-4 and CCS-1 studies show that more than half of the lives are saved by ACE inhibitor treatment within the first week of therapy. Although the benefit from ACE inhibitors is larger in patients presenting with congestive heart failure (Killip class > 1), the number of lives saved in patients at low risk, who represent the majority of the population, is relevant. This supports the approach of treating all hemodynamically stable MI patients. Treatment could be stopped after about 1 month in patients without evidence of LVD while those with LVD should follow a long-term therapy with ACE inhibitors.",
keywords = "Angiotensin-converting enzyme, Clinical trials, Myocardial infarction",
author = "Roberto Latini and Maggioni, {Aldo P.} and Giulio Zuanetti",
year = "1995",
month = "12",
language = "English",
volume = "87",
pages = "16--22",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Myocardial infarction

T2 - When and how should we initiate treatment with ACE inhibitors?

AU - Latini, Roberto

AU - Maggioni, Aldo P.

AU - Zuanetti, Giulio

PY - 1995/12

Y1 - 1995/12

N2 - Recent trials have shown that angiotensin-converting enzyme (ACE) inhibitors can reduce mortality and the occurrence of severe left ventricular dysfunction (LVD) when started within the first day after acute myocardial infarction and continued for 4-6 weeks thereafter. When started within this time window, ACE inhibitors are safe in relatively unselected myocardial infarction (MI) patients provided they are clinically and hemodynamically stable. GISSI-3, ISIS-4 and CCS-1 studies show that more than half of the lives are saved by ACE inhibitor treatment within the first week of therapy. Although the benefit from ACE inhibitors is larger in patients presenting with congestive heart failure (Killip class > 1), the number of lives saved in patients at low risk, who represent the majority of the population, is relevant. This supports the approach of treating all hemodynamically stable MI patients. Treatment could be stopped after about 1 month in patients without evidence of LVD while those with LVD should follow a long-term therapy with ACE inhibitors.

AB - Recent trials have shown that angiotensin-converting enzyme (ACE) inhibitors can reduce mortality and the occurrence of severe left ventricular dysfunction (LVD) when started within the first day after acute myocardial infarction and continued for 4-6 weeks thereafter. When started within this time window, ACE inhibitors are safe in relatively unselected myocardial infarction (MI) patients provided they are clinically and hemodynamically stable. GISSI-3, ISIS-4 and CCS-1 studies show that more than half of the lives are saved by ACE inhibitor treatment within the first week of therapy. Although the benefit from ACE inhibitors is larger in patients presenting with congestive heart failure (Killip class > 1), the number of lives saved in patients at low risk, who represent the majority of the population, is relevant. This supports the approach of treating all hemodynamically stable MI patients. Treatment could be stopped after about 1 month in patients without evidence of LVD while those with LVD should follow a long-term therapy with ACE inhibitors.

KW - Angiotensin-converting enzyme

KW - Clinical trials

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=13344278676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344278676&partnerID=8YFLogxK

M3 - Article

C2 - 8681316

AN - SCOPUS:13344278676

VL - 87

SP - 16

EP - 22

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - SUPPL. 1

ER -